Anzeige
Mehr »
Login
Sonntag, 03.07.2022 Börsentäglich über 12.000 News von 664 internationalen Medien
Breaking News! Geniale Übernahme - NFT Technologies im Fokus der Anleger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKSD ISIN: NO0010851603 Ticker-Symbol: 7UM 
Stuttgart
01.07.22
15:38 Uhr
6,820 Euro
+0,180
+2,71 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ULTIMOVACS ASA Chart 1 Jahr
5-Tage-Chart
ULTIMOVACS ASA 5-Tage-Chart
RealtimeGeldBriefZeit
6,8607,14002.07.

Aktuelle News zur ULTIMOVACS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrUltimovacs' malignant melanoma study fully recruited-
DoUltimovacs ASA: Mandatory notification of trade by primary insider108Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK...
► Artikel lesen
DoUltimovacs ASA: Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma142Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival...
► Artikel lesen
ULTIMOVACS Aktie jetzt für 0€ handeln
21.06.Ultimovacs - Positive Phase I survival data in melanoma190Ultimovacs has announced positive two-year overall survival (OS) data from a Phase I study (n=30) of UV1, a potential universal cancer vaccine, in combination with PD-1 immunotherapy (pembrolizumab...
► Artikel lesen
20.06.Ultimovacs ASA: Ultimovacs' UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial23830 patients treated with UV1/pembrolizumab24-month survival rate of 73%Promising survival data follows encouraging clinical response rates and good safety Oslo, 20 June 2022: Ultimovacs ASA ("Ultimovacs")...
► Artikel lesen
15.06.Ultimovacs - Patient enrolment continues; catalysts approach242Readouts from Ultimovacs' clinical pipeline inch closer as patients continue to enrol in the company's busy clinical programme. UV1, Ultimovacs' potential universal cancer vaccine, is being investigated...
► Artikel lesen
25.05.Ultimovacs ASA: Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy333Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 yearsUV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint...
► Artikel lesen
23.05.BioStock Studio: An in-depth look at Ultimovacs' cancer vaccine1
17.05.Ultimovacs keeps delivering in Q11
13.05.Ultimovacs - UV1 Phase II data flow creeps closer239Management provided an update on the clinical progress of lead candidate UV1 in six clinical trials in conjunction with its Q122 financial results. Enrolment in the INITIUM (first-line metastatic malignant...
► Artikel lesen
12.05.Ultimovacs ASA: First quarter 2022 result presentation181Oslo, 12 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its first quarter 2022 results today. The presentation...
► Artikel lesen
10.05.Ultimovacs ASA: Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting209UV1 immune monitoring data from three Phase I/IIa clinical trials show dynamic T cell responses lasting up to 7.5 yearsMeasurable UV1-specific immune response in 91% of patients when combined with checkpoint...
► Artikel lesen
05.05.Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation209Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation Oslo, 5 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines...
► Artikel lesen
26.04.Ultimovacs protects cancer vaccine technology until 20371
22.04.Ultimovacs ASA: Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations195Extends protection for UV1 vaccine-checkpoint inhibitor combinations until at least 2037Covers UV1 with CTLA-4, PD-1 or PD-L1 checkpoint inhibitors Oslo, 22 April 2022: Ultimovacs ASA ("Ultimovacs")...
► Artikel lesen
21.04.Ultimovacs ASA - Share Option Program323Oslo, 21 April 2022: On the basis of the approval by the General Meeting on 21 April 2022 to authorize the Board of Directors of Ultimovacs ASA (the 'Company', OSE ticker "ULTI") to issue new shares...
► Artikel lesen
21.04.Ultimovacs ASA - Annual General Meeting held on 21 April 2022225Oslo, 21 April 2022: Ultimovacs ASA held its annual general meeting today 21 April 2022. All the matters on the agenda were approved. All board members were re-elected for a period of one year...
► Artikel lesen
08.04.Ultimovacs ASA: Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development440TET platform shows efficient T cell priming and beneficial safety profile Data supported clinical transition to ongoing TENDU Phase I trialTET platform offers potential to strengthen T cell response...
► Artikel lesen
08.04.Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting292Oslo, 08 April 2022: In connection with the Annual General Meeting of Ultimovacs ASA to be held on 21 April 2022, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting...
► Artikel lesen
30.03.Ultimovacs ASA: Ultimovacs to host Investor Days 2022: Meet the Team322Oslo, 30 March 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, will host Investor Days 2022: Meet the Team events in several cities....
► Artikel lesen
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1